nepafenac (Nevanac®)

Reference No. 1509

Publication date:

16/08/2013

Last review date:

30/09/2016

Appraisal information

nepafenac (Nevanac®) 1 mg/ml eye drops

Company:	Alcon Laboratories (UK) Ltd
BNF category:	Eye
NMG meeting date:	19/06/2013
AWMSG meeting date:	17/07/2013

Submission Type:	Full Submission
Status:	Recommended
Advice No:	1813
Ministerial ratification:	14/08/2013

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Nepafenac (Nevanac®) is recommended for use within NHS Wales for reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Final Appraisal Recommendation (FAR)

Download

nepafenac (Nevenac) 1509 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

nepafenac (Nevanac) 1509 ASAR

Clinical Expert (CE) Summary

Download

nepafenac (Nevanac) 1509 CE summary